Prevention of otitis media: Now a reality?

Vaccine

Volumn 27, Issue 42, 2009, Pages 5748-5754

  Schuerman, Lode ^a   Borys, Dorota ^a   Hoet, Bernard ^a   Forsgren, Arne ^b   Prymula, Roman ^c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b University Hospital Malmö   (Sweden)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Invasive pneumococcal disease; Non typeable Haemophilus influenzae (NTHi); Otitis media; Pneumococcal conjugate vaccine; Protein D; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; SYNFLORIX; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; CHILDHOOD DISEASE; DRUG EFFICACY; ECONOMIC ASPECT; HAEMOPHILUS INFLUENZAE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; OTITIS MEDIA; PRIORITY JOURNAL; REVIEW; SEROTYPE; SOCIAL ASPECT; STREPTOCOCCUS PNEUMONIAE;

BACTERIAL PROTEINS; CARRIER PROTEINS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; IMMUNOGLOBULIN D; LIPOPROTEINS; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 69849108072     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.070     Document Type: Review

References (72)

1. Klein J.O. Otitis media. Clin Infect Dis 19 (1994) 823-832
2. Cripps A.W., Otczyk D.C., and Kyd J.M. Bacterial otitis media: a vaccine preventable disease?. Vaccine 23 (2005) 2304-2310
3. Brouwer C.N., Rovers M.M., Maillé A.R., Veenhoven R.H., GrobbeeDE, Sanders E.A., et al. The impact of recurrent acute otitis media on the quality of life of children and their caregivers. Clin Otolaryngol 30 (2005) 258-265
4. Melegaro A., Edmunds W.J., Pebody R., Miller E., and George R. The current burden of pneumococcal disease in England and Wales. J Infect 52 (2006) 37-48
5. Kvaerner K., Liese J., Arguedas A., Pelton S., Dean C., and Schilder A. A multinational survey highlights the clinical burden of children with otitis media. Presented at the 26th annual European society for paediatric infectious disease. May 13-17, 2008, Graz, Austria (2008) [abstract]
6. Stolk E., Mangen M.J., Wolleswinkel J., and LaPlante S. Healthcare use and societal burden due to childhood otitis media in 7 EU countries. Presented at the 26th annual European society for paediatric infectious disease. May 13-17, 2008, Graz, Austria (2008) [abstract]
7. Froom J., Culpepper L., Grob P., Bartelds A., Bowers P., Bridges-Webb C., et al. Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network. Br Med J 300 (1990) 582-586
8. Schilder A.M.G., Lok W., and Rovers M.M. International perspectives on management of acute otitis media: a qualitative review. Int J Pediatr Otorhinolaryngol 68 (2004) 29-36 [Review]
9. Godfroid F., and Moudoulaud J. A multi-country analysis of antibiotic use for otitis media in children aged 5 years or younger. Presented at 26th annual meeting of the European society for paediatric infectious diseases. May 13-17, 2008, Graz, Austria (2008) [abstract]
10. Niemelä M., Uhari M., Möttönen M., and Pokka T. Costs arising from otitis media. Acta Pediatr 88 (1999) 553-556 [Original article] See also comment in Alsarraf R. and Gates G.A. Acta Paediatr 1999;88:487-8
11. Petit G., De Wals P., Law B., Tam T., Erickson L.J., Guay M., et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 14 (2003) 215-220
12. American Academy of Pediatrics and American Academy of Family Physicians Clinical Practice Guideline. Diagnosis and management of acute otitis media. Pediatrics 113 (2004) 1451-1465
13. Alsarraf R., Jung C.J., Perkins J., Crowler C., Alsarraf N.W., and Gates G.A. Measuring the indirect and direct costs of acute otitis media. Arch Otolaryngol Head Neck Surg 125 (1999) 12-18
14. Gehanno P., Panajotopoulos A., Barry B., Nguyen L., Levy D., Bingen E., et al. Microbiology of otitis media in the Paris, France, area from 1987 to 1997. Pediatr Infect Dis J 20 (2001) 570-573
15. Leibovitz E., Jacobs M.R., and Dagan R. Haemophilus influenzae. A significant pathogen in acute otitis media. Pediatr Infect Dis J 23 (2004) 1142-1155
16. Pichichero M.E. Evolving shifts in otitis media pathogens: relevance to a managed care organization. Am J Manag Care 11 (2005) S192-S201
17. Guevara S., Soley C., Arguedas A., Porat A., and Dagan R. Seasonal distribution of otitis media pathogens among Costa Rican children. Pediatr J Infect Dis 27 1 (2008) 12-16
18. Plasschaert A.I., Rovers M.M., Schilder A.G., Verheij T.J., and Hak E. Trends in doctor consultations, antibiotic prescriptions, and specialist referrals for otitis media in children: 1995-2003. Pediatrics 117 (2006) 1879-1886
19. Finkelstein J.A., Metlay J.P., Davis R.L., Rifas-Shiman S.L., Dowell S.F., and Platt R. Antimicrobial use in defined populations of infants and young children. Arch Pediatr Adolesc Med 154 (2000) 395-400
20. Goossens H., Ferech M., Vander Stichele R., Elseviers M., and ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365 9459 (2005) 548-549
21. Yamanaka N., Hotomi M., and Billal D.S. Clinical bacteriology and immunology in acute otitis media in children. J Infect Chemother 14 3 (2008) 180-187
22. Block S.L., Hedrick J., Harrison C.J., Tyler R., Smith A., Findlay R., et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis. Pediatr Infect Dis J 23 (2004) 829-833
23. Farrell D.J., Klugman K.P., and Pichichero M. Increased antimicrobial resistance among non-vaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26 (2007) 123-128
24. Bishai W.R. Clinical significance of pneumococcal resistance and factors influencing outcomes. Treat Respir Med 4 Suppl. 1 (2005) 19-23
25. Whitney C.G., and Klugman K. Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. Semin Pediatr Infect Dis 15 (2004) 86-93
26. Casey J.R., and Pichichero M.E. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 23 (2004) 824-828
27. Arguedas A., Dagan R., Soley C., Loaiza C., Knudsen K., Porat N., et al. Microbiology of otitis media in Costa Rican children, 1999 through 2001. Pediatr Infect Dis J 22 (2003) 1063-1068
28. Leibovitz E., Asher E., Piglansky L., Givon-Lavi N., Satran R., Raiz S., et al. Is bilateral acute otitis media clinically different than unilateral acute otitis media?. Pediatr Infect Dis J 26 (2007) 589-592
29. Pichichero M.E., Casey J.R., Hoberman A., and Schwartz R. Pathogens causing recurrent and difficult-to-treat acute otitis media, 2003-2006. Clin Pediatr (Phila) 47 (2008) 901-906
30. Black S., Shinefield H., Baxter R., Austrian R., Bracken L., Hansen J., et al. Post licensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23 (2004) 485-489
31. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (2007) 1179-1186
32. Vestrheim D.F., Lovoll O., Aaberge I.S., Caugan T.D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26 (2008) 3277-3281
33. Hausdorff W.P., Bryant J., Paradiso P.R., and Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 (2000) 100-121
34. GAVI PneumoADIP Report. Pneumococcal regional serotype distribution for pneumococcal AMC TPP. Codebook to assess whether a pneumococcal vaccine meets the pneumococcal AMC target product profile for regional vaccine serotype coverage; November 2008. Available at: http://www.vaccineamc.org/files/TTP_Codebook.pdf.
35. Beall B., McEllistrem M.C., Gertz Jr. R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001 and 2002. J Clin Microbiol 44 (2006) 999-1017
36. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (7VCRM) serotypes in the United States during the era of widespread 7VCRM vaccination, 1998-2004. J Infect Dis 196 (2007) 1346-1354
37. Aguiar S.I., Serrano I., Pinto F.R., Melo-Cristino J., Ramirez M., and Portuguese Surveillance Group for the Study of Respiratory Pathogens. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 14 9 (2008) 835-843
38. Grivea I.N., Panagiotou M., Tsantouli A.G., and Syrogiannopoulos G.S. Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr Infect Dis J 27 6 (2008) 519-525
39. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Carcia J.J., and Pallares R. Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of 7-valent conjugate vaccine. CID 46 (2008) 174-182
40. Obando I., Munoz-Almagro C., Arroyo L.A., Tarrago D., Sanchez-Tatay D., Moreno- Perez D., et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 14 9 (2008) 1390-1397
41. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 (2001) 403-409
42. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000) 187-195
43. Kilpi T., Ahman H., Jokinen J., Lankinen K.S., Palmu A., Savolainen H., et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. CID 37 (2003) 1155-1164
44. Palmu A., Jokinen J., and Kilpi T. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 26 (2008) 2466-2470
45. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 (2006) 865-873
46. Poehling K.A., Szilagyi P.B., Grijalva C.G., Martin S.W., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119 (2007) 707-715
47. Brueggemann A.B., Peto T.E.O., Creek D.W., Butler J.C., Kristinsson K.G., and Spratt B.G. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 190 (2004) 1203-1211
48. Hausdorff W.P., Feikin D.R., and Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet 5 (2005) 83-93
49. Hausdorff W.P. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 25 13 (2007) 2406-2412
50. Rückinger S., von Kries R., Siedler A., and van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 28 2 (2009) 118-122
51. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., and Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72 (2004) 5383-5391
52. Dagan R., Poolman J.T., and Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and co-administration of CRM197 conjugates. Expert Rev Vaccines 7 1 (2008) 97-115
53. Nurkka A., Joensuu J., Henckaerts I., Peeters P., Poolman J., Kilip T., et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J 23 11 (2004) 1008-1014
54. Novotny L.A., Jurcisek J.A., Godfroid F., Poolman J.T., Denoel P.A., and Bakaletz L.O. Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Vaccine 24 (2006) 4804-4811
55. Akkoyunlu M., Ruan M., and Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect Immun 59 (1991) 1231-1238
56. Poolman J.T., Bakaletz L., Cripps A., Denoel P.A., Forsgren A., Kyd J., et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 19 Suppl. 1 (2000) 108-115
57. Forsgren A., Riesbeck K., and Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 46 (2008) 726-731
58. Duim B., Ruiter P., Bowler L.D., Dankert J., and van Alphen L. Sequence variation in the hpd gene of non-encapsulated Haemophilus influenzae isolated from patients with chronic bronchitis. Gene 191 (1997) 57-60
59. Janson H., Melhus A., Hermansson A., and Forsgren A. Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis mode. Infect Immun 62 (1994) 4848-4854
60. Janson H., Carlén B., Cervin A., Forsgren A., Magnusdottir A.M., Lindberg S., et al. Effects on the ciliated epithelium of protein D-producing and -non-producing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis 180 (1999) 737-746
61. Ahren I.L., Janson H., Forsgren A., and Riesbeck K. Protein D expression promotes the adherence and internalization of non-typeable Haemophilus influenzae into human monocytic cells. Microb Pathog 31 3 (2001) 151-158
62. Akkoyunlu M., Janson H., Ruan M., and Forsgren A. Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae. Infect Immun 64 (1996) 4586-4592
63. Kyd J.M., and Cripps A.W. Potential of a novel protein, OMP26, from non-typeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infect Immun 66 (1998) 2272-2278
64. Bakaletz L.O., Kennedy B.J., Novotny L.A., Duquesne G., Cohen J., and Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 67 6 (1999) 2746-2762
65. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367 (2006) 740-748
66. Schuerman L., Prymula R., Henckaerts I., and Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 25 (2007) 1962-1968
67. Schuerman L., Prymula R., Chrobok V., Dieussaert I., and Poolman J. Kinetics of the immune response following pneumococcal PD conjugate vaccination. Vaccine 25 (2007) 1953-1961
68. Wysocki J., Tejedor C., Grunert D., Konior R., Garcia-Sicilia J., Knuf M., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 28 (2009) S77-88
69. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsene J.-P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28 (2009) S66-S76
70. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J et al. Limited clinical benefit but reduced antibody responses to pediatric vaccines following prophylactic paracetamol/acetaminophen administration, Lancet (2009), In press.
71. Bermal N., Szenborn L., Chrobot A., Alberto E., Lommel P., Gatchalian S., et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 28 (2009) S89-S96
72. Novotny L., Bakaletz L., Poolman, and Denoel P. 10-Valent protein-D conjugate vaccine induces protection against NTHi otitis media in a chinchilla model (2008), HinMax, Rotterdam, Netherlands [abstract]